MAR 11, 2015 3:00 PM PDT

Doctor Drug Ratings Give Patients More Power

WRITTEN BY: Robert Woodard
A March 11 article on wired.com brings our attention to a new online review service, joining the likes of Yelp, Amazon, Netfllix and Etsy.

Except this time, the service reviews prescription drugs.
4-star rating? Call your pharmacist.
Who needs that? Turns out that a lot of people do. When it comes to prescription medication, too often, we take what the doctor orders, no questions asked. That's a problem. According to the Mayo Clinic, nearly 70 percent of Americans take prescription drugs, and sometimes-maybe too often the doctors prescribing those drugs are on the payrolls of the very companies that sell them.

Enter RateRx. Ron Gutman, CEO of the digital health startup HealthTap, aims to take on this lack of transparency. RateRx will let doctors from all over the world rate the effectiveness of certain medications for certain ailments. They'll also be able to leave comments about those drugs and rate other doctors' answers. From that data, patients will be able to surface the best answers to make informed choices about the drugs they take.

"Healthcare is like a black box. We're buying blind," Gutman says. "But obviously there are opinions out there, and there are multiple medications to treat certain things. It's good if we get informed about the state of the art in healthcare today."

RateRx is an extension of the work HealthTap is already doing to address the problem of the low-quality medical advice that runs rampant online. Its core business allows users to ask HealthTap's network of 67,000 doctors (and counting) any medical question and get an answer for free any time of the day. After serving up 2.7 billion doctor answers since its founding in 2010, the HealthTap team realized that some of the most frequently asked questions were about prescription drugs, and they decided to develop a product that spoke directly to that strong interest.

HealthTap, of course, isn't the only company that sees this lack of clarity as an opportunity. Iodine, a startup co-founded by former WIRED executive editor Thomas Goetz, crowdsources patient reviews, and presents them alongside clinical trial data and input from pharmacists. Another site, TheNNT.com, rates drugs based on the number of people who would need to take a drug in order for it to help one person - a statistical measure known as the "number needed to treat." And Google has been working with the Mayo Clinic to create a database of information on commonly searched medical conditions, which includes lists of frequently used treatments for each.

No doubt, this is only the beginning. It's too early to say if these new services will become the most trusted source for this type of information. But they may take some power from big pharma and put in the hands of patients.

Source: wired.com
About the Author
You May Also Like
APR 27, 2020
Earth & The Environment
APR 27, 2020
Air pollution increasing in Africa
New research published in Environmental Research Letters reports that air pollution in Africa has increased significantl ...
APR 30, 2020
Chemistry & Physics
APR 30, 2020
Spotting COVID-19 Symptoms from a Safe Distance
As the fight to contain coronavirus infection continues, many essential service providers such as healthcare, power, and ...
MAY 19, 2020
Clinical & Molecular DX
MAY 19, 2020
Hormone Levels in Infants Linked to Autism
  A potential biomarker for autism has been identified in infants: the levels of a hormone called vasopressin found ...
MAY 21, 2020
Cancer
MAY 21, 2020
A New Player in the Regulation of Cancer's Microenvironment
Breast cancer is one of the most common cancers in the world.  Triple-negative breast cancer (TNBC) is a sub-type o ...
MAY 20, 2020
Cardiology
MAY 20, 2020
Hearts Beat Differently to Music
Does some music relax you, does other music excite you? There is a physiological response to music, and your heart may b ...
MAY 25, 2020
Cancer
MAY 25, 2020
Using Transcription Factors to Predict Bladder Cancer Prognosis
Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, wi ...
Loading Comments...